eetkid
Posted - 2 days ago
$KRBP nice load near low 2s doubt we see 1s often this year. Might place an order right under 2.00
11thestate
Posted - 4 days ago
$KRBP The deadline has passed but you can still file for a late claim
Pukkaa56
Posted - 5 days ago
$KRBP GM,today maybe pr.
Medpower
Posted - 1 week ago
$INAB and $KRBP 🚀
JigssawHat
Posted - 1 week ago
$KRBP
GinnyMama
Posted - 1 week ago
$KRBP KIROMIC BIOPHARM Dear Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Kiromic BioPharma, Inc. (the “Registrant”) hereby requests the immediate withdrawal of the above-referenced registration statement, together with all exhibits and amendments thereto (the “Registration Statement”). The Registration Statement was initially filed with the Securities and Exchange Commission (the “SEC”) on June 29, 2023. The Registrant is requesting to withdraw the Registration Statement because it has elected not to pursue the sale of securities pursuant to the Registration Statement at this time. The Registrant confirms that no securities were sold in connection with the offering contemplated by the Registration Statement. Please direct any questions or comments regarding this correspondence to our counsel, Jeffrey Fessler of Sheppard Mullin Richter & Hampton LLP, at (212) 634-3067. Thank you for your assistance in this matter. Sincerely,
Orlandotrader
Posted - 1 week ago
$KRBP WTF!!! Too Funny. 16 Thousand shares knocked this down to 1.70. One Thousand shares and back to 3.05. Folks don’t Key go of your Shares!!!! Know what you Own.
Allperspective
Posted - 1 week ago
$KRBP im guessing the note that was converted last week by the debt investor for all those shares were just sold and released into the market ? Does anyone know what price he converted that note to shares at ?
Orlandotrader
Posted - 1 week ago
$KRBP Meaningless Bullshit trade on this Fake index!!! Sad
GinnyMama
Posted - 2 weeks ago
$KRBP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 KIROMIC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-39619 46-4762913 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 7707 Fannin, Suite 200 Houston, TX, 77054 On March 28, 2024, Kiromic BioPharma, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with the holder of promissory notes of the Company (the “Holder”) pursuant to which the Holder agreed to exchange aggregate principal amount of $8 million of the Company’s 25% Senior Secured Convertible Promissory Notes (the “Exchange Notes”) for 8,000 shares of Series D Convertible Voting Preferred Stock
GinnyMama
Posted - 2 weeks ago
$KRBP Item 1.01 Entry into a Material Definitive Agreement. On March 28, 2024, Kiromic BioPharma, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with the holder of promissory notes of the Company (the “Holder”) pursuant to which the Holder agreed to exchange aggregate principal amount of $8 million of the Company’s 25% Senior Secured Convertible Promissory Notes (the “Exchange Notes”) for 8,000 shares of Series D Convertible Voting Preferred Stock (the “Series D Preferred Stock”).
11thestate
Posted - 2 weeks ago
$KRBP agreed to settle $2.3M with shareholders to end claims over its IPO in 2021. Claim submission info and details:https://11thestate.com/cases/kiromic-ipo-settlement Who is eligible to get a payout? All persons and entities that purchased or otherwise acquired (a) Kiromic common stock pursuant and/or traceable to the Offering Documents and/or (b) Kiromic common stock between June 25, 2021 and February 2, 2022, both dates inclusive.
Cli1
Posted - 2 weeks ago
$KRBP
GinnyMama
Posted - 2 weeks ago
$KRBP KIROMIC BIOPHARMA REPORTS FAVORABLE SAFETY, TOLERABILITY, AND EARLY EFFICACY FROM THIRD PATIENT IN DELTACEL-01 CLINICAL TRIAL Apr 02, 2024 Download PDF Trial’s Safety Monitoring Committee Recommends Maintaining Initial Cell Dose Level for Next Cohort of Patients HOUSTON--(BUSINESS WIRE)--Apr. 2, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. Preliminary imaging results for this last patient in the first cohort, obtained six weeks after beginning treatment, show a favorable safety and tolerability profile, and promising early efficacy for the Deltacel™ treatment.
GinnyMama
Posted - 2 weeks ago
$KRBP KIROMIC BIOPHARMA REPORTS FAVORABLE SAFETY, TOLERABILITY, AND EARLY EFFICACY FROM THIRD PATIENT IN DELTACEL-01 CLINICAL TRIAL
Orlandotrader
Posted - 2 weeks ago
$KRBP Early findings from the first three patients enrolled in Deltacel-01 – especially the consistent favorable safety profile and signs of efficacy – reinforce our commitment to advancing Deltacel™ as a potential off-the-shelf, Gamma Delta T-cell therapy. We are particularly pleased to observe a growing body of evidence that Deltacel™ could be a significant step forward in treating cancer. Our team is inspired by these results and remains dedicated to further testing the therapeutic potential of Deltacel™, as confirmed by SMC’s recommendation not to increase the Deltacel™ dose level. Achieving a therapeutic effect with the initial dose level will benefit patients, while not having to test additional dose levels will shorten the overall length of the Phase 1 clinical trial," said Pietro Bersani, Chief Executive Officer of Kiromic BioPharma.
Orlandotrader
Posted - 2 weeks ago
$KRBP Additionally, the Deltacel-01 Safety Monitoring Committee (SMC) convened to analyze all preliminary patient data received to date and to determine the next phase of the trial. After reviewing safety and efficacy findings from the first cohort of three patients, the SMC recommended not to escalate the cell dose level and instead to treat the next cohort of patients at the initial dose level. This unanimous recommendation was based on encouraging preliminary data supporting Deltacel™ safety and tolerability, and evidence of anti-tumor activity.
Orlandotrader
Posted - 2 weeks ago
$KRBP Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies.
privatebio
Posted - 03/28/24
$XLO will not be surprised if $krbp will move up like this next week after data release for the third patient.
privatebio
Posted - 03/28/24
$XELA $ADTX $KRBP $PIK
privatebio
Posted - 03/28/24
$KRBP $XLO
privatebio
Posted - 03/28/24
$KRBP One day sooner than expected we will wake up with a $XLO kind news deal
Orlandotrader
Posted - 03/26/24
$KRBP Bullish Pennant has Formed! Awaiting the Data from Third Patient Dosed. Maybe some more Insight on Patient One.
OptionsGalore
Posted - 03/25/24
$KRBP they may get buyout offers before it gets this high. No doubt in my mind this can clear $30M Market cap within a couple of years unless they get bought out.
ca_rott1487
Posted - 03/21/24
$KRBP agreed to settle $2.3 million with shareholders to end claims over its IPO in 2021. Claim submission info and details:https://11thestate.com/cases/kiromic-ipo-settlement
privatebio
Posted - 1 month ago
$KRBP Mark it : will be two digits stock if third patients efficacy data good. Stay tuned in coming days. "Kiromic expects to announce initial safety, tolerability, and preliminary efficacy results from the third patient enrolled in Deltacel-01 by the end of March"
OptionsGalore
Posted - 1 month ago
$KRBP no question they will apply for uplisting soon.
OptionsGalore
Posted - 1 month ago
$KRBP should be $100